To manufacture sterile aqueous presentations for regional nerve blocks in food-producing and companion animals, chloroprocaine hydrochloride (Nesacaine), 2-diethylaminoethyl 4-amino-2-chlorobenzoate hydrochloride, is dissolved in Water for Injection at 10 mg/mL or 20 mg/mL (1% w/v and 2% w/v). Starting API is released against 98.0–102.0% assay on dried basis, with related substances controlled by the USP monograph and residual solvents per ICH Q3C. Sodium chloride is added to 280–320 mOsm/kg, and the bulk solution is acidified to pH 2.7–4.0 before API addition because the ester linkage undergoes accelerated hydrolysis above pH 5.0. Mixing is performed in Type 316L stainless steel tanks under a nitrogen overlay at 20–25 °C; high-shear dispersion is not required because the hydrochloride salt is freely water-soluble, but vortex depth is controlled to avoid cavitation and oxygen entrainment. The bulk solution is passed through a 0.45 µm polyethersulfone clarification filter, then sterilized through a 0.22 µm membrane and filled into Type I borosilicate glass vials under EU GMP Annex 1 Grade A conditions. Terminal autoclaving is evaluated only after heat-stability studies because ester degradation and pH shift during steam exposure can vary with vial headspace and stopper composition. Multi-dose presentations may include methylparaben 0.1% w/v; single-dose vials are preservative-free. The finished injection is tested against USP <1>, USP <71>, USP <85>, USP <788>, USP <790>, and 21 CFR Part 211. Chlorobutyl rubber stoppers with fluoropolymer coating reduce sorption and extractable alkalinity. The terminal product is intended for infiltration anesthesia, peripheral nerve block, and epidural administration in veterinary surgery when the attending veterinarian determines that the short duration of action is appropriate. For food-producing species, withdrawal periods are not established uniformly; use is governed by veterinary prescription and national residue-control legislation. Production records document pH at filling, oxygen headspace below 2% v/v, and subvisible particulate counts per USP <789> for small-volume parenterals.

What Limits Reconstituted Yield in Lyophilized Chloroprocaine Hydrochloride Powders?

Because veterinary facilities require extemporaneous dilution for nerve block procedures, lyophilized chloroprocaine hydrochloride is manufactured as a sterile powder for reconstitution. The formulation typically contains 10–30 mg chloroprocaine hydrochloride per vial and mannitol as a crystalline bulking agent at 20–40 mg/mL in the pre-lyophilization solution. Citric acid or dilute hydrochloric acid adjusts the bulk solution to pH 3.0–4.5; sodium hydroxide is used only in limited increments because local pH excursions above 8.0 cleave the ester bond within minutes. The solution is filtered through a 0.22 µm sterilizing membrane and filled into 5 mL tubular glass vials with a target fill volume of 2.0 mL. Freeze-drying proceeds with shelf pre-cooling to −40 °C, annealing at −10 °C for 2 h, primary drying at −25 °C and 0.20 mbar, and secondary drying at 25 °C until residual moisture is below 1.0% w/w by Karl Fischer titration. Reconstitution with 2 mL Sterile Water for Injection yields a nominal 5–15 mg/mL solution; actual potency depends on fill assay and sublimation losses. The principal process yield constraints are vial breakage during freezing, ejection of amorphous material if the formulation lacks sufficient crystallinity, and pH shift during mannitol crystallization. Published data for chloroprocaine-specific lyophilization cycles are limited; manufacturers using mannitol-based matrices typically rely on collapse temperature data from differential scanning calorimetry and freeze-drying microscopy rather than generic cycles. The finished cake is a white to off-white plug with moisture ≤1.0%, endotoxin limit ≤0.25 EU/mg, and sterility per USP <71>. Terminal packaging under dry nitrogen with an aluminum flip-off cap maintains the moisture barrier. The powder is stored at 2–8 °C and protected from light because photolytic degradation produces 4-amino-2-chlorobenzoic acid, which reduces assay and may alter pH after reconstitution.

For veterinary oral transmucosal tablets, direct compression of chloroprocaine hydrochloride is performed at doses of 10 mg and 25 mg, although swallowed administration is not the primary route. The API is milled and screened through a 30 mesh sieve to avoid agglomerates larger than 600 µm. A typical direct-compression matrix contains 5–15% w/w chloroprocaine hydrochloride, mannitol as brittle diluent 60–75% w/w, crospovidone 2–5% w/w as superdisintegrant, and magnesium stearate 0.5–1.0% w/w as lubricant. Citric acid 1–2% w/w may be added to maintain an acidic microenvironment after tablet erosion in salivary pH 6.8–7.4; without acidification, the free base can precipitate on the mucosal surface and reduce membrane permeation. Blending is carried out in a V-blender at 25 rpm for 15–20 min after geometric dilution of the API with mannitol. Tablet compression uses 8 mm B-tooling on a rotary press with target hardness 40–80 N and friability <1.0% per USP <1216>. Content uniformity is verified by USP <905>, and dissolution is assessed with 0.01 N hydrochloric acid at 37 °C using USP Apparatus II at 50 rpm. Batch records document the effect of relative humidity; granulation is avoided where possible because the hydrochloride salt deliquesces above 60% RH, and magnesium stearate overblending beyond 5 min can reduce tablet tensile strength by coating the brittle excipient. The terminal tablets are intended for veterinary buccal placement or oral transmucosal protocols where a short-duration local anesthetic effect is sought. Published clinical efficacy data for this specific veterinary tablet configuration are limited, and the absence of an approved veterinary tablet product means compounding is governed by FDA GFI #256 in the United States and equivalent national veterinary compounding provisions. For swallowed capsules and tablets, presystemic esterase hydrolysis in the gastrointestinal tract is expected to limit systemic exposure; this is a biochemical boundary, not a formulation defect.

When Capsule Filling Replaces Direct Compression for Low-Dose Veterinary Units

When the chloroprocaine hydrochloride dose must be individualized below 10 mg or when a swallowable unit is required for hospital dispensing, hard gelatin capsule filling is selected. The API is first mixed with lactose monohydrate via geometric dilution to a 1–5% w/w triturate because direct weighing of pure API for each capsule produces fill-weight variability above 5% CV. The triturate is then blended with pregelatinized starch and colloidal silicon dioxide 0.5–1.0% w/w to improve flow through an automatic dosator capsule machine. Empty capsule size is selected between size 3 and size 1 depending on final fill weight; target fill weight is calculated from tapped bulk density, which is measured after 1250 taps per USP <616>. Lubrication with magnesium stearate is limited to 0.5% w/w and blended for 3–5 min because prolonged mixing increases hydrophobicity and slows capsule dissolution. The capsule shells are stored at 40–50% RH and 15–25 °C before filling to avoid brittle fracture or softening. Weight variation is tested according to USP <2091> or USP <905> for capsules, and assay is performed by high-performance liquid chromatography with ultraviolet detection and peak purity confirmation against a reference standard. Swallowed capsules containing chloroprocaine hydrochloride are not a standard systemic dosage form; the presystemic esterase activity in plasma and tissues rapidly degrades the molecule, so the terminal product is typically used for localized oral-mucosal studies or as a compounding intermediate. Manufacturers packaging this API in capsule form must document that the shell material does not contain reactive aldehydes that can crosslink the primary amine at higher temperature. The finished capsules are stored in induction-sealed high-density polyethylene bottles with desiccant and are assigned a retest date based on ICH Q1A stability data, not default 24-month extrapolation.

Granule and Premix Homogeneity and Regulatory Boundaries

In the United States and European Union, chloroprocaine hydrochloride is not approved as a feed additive for food-producing animals, and extralabel use in medicated feed is prohibited under 21 CFR 530.13. Consequently, granule and premix manufacture is confined to research protocols, non-food species in jurisdictions that permit it, or authorized investigational veterinary medicinal studies under Regulation (EU) 2019/6. Technical work on granule formulations addresses dry blending, wet granulation, and spray layering onto lactose granules. For a laboratory-scale premix, chloroprocaine hydrochloride is first ground to D90 < 150 µm and triturated with lactose monohydrate in a 1:10 ratio before addition to a double-ribbon blender containing 0.1–1.0% w/w active premix. Mixing time is set by powder conductivity or near-infrared homogeneity studies; acceptance is often a coefficient of variation ≤5.0% across 10 sampling points. Wet granulation with 5–10% w/w povidone solution in isopropyl alcohol is possible, but drying must not exceed 40 °C because the ester linkage degrades at higher temperatures in the presence of moisture. The resulting granules are passed through a 12 mesh screen and dried to ≤2.0% loss on drying per USP <731>. Fluid-bed granulation and spray-dried dispersions are generally avoided unless the API is protected from hot inlet air above 50 °C. The terminal premix is not offered as a growth-promotion or feed-efficiency product; any label statement describing nutrient or zootechnical effects would be noncompliant because chloroprocaine hydrochloride has no recognized nutritional role. Batches intended for research are labeled with the chemical name, quantity, study number, and the statement “not for food-producing animals.” The manufacturing facility must still operate under ICH Q7 active pharmaceutical ingredient GMPs if the premix is shipped across international borders as an API or intermediate.

Sterile Irrigation Solutions Require pH, Particulate, and Endotoxin Control

Aseptically compounded topical-mucosal irrigation solutions contain chloroprocaine hydrochloride at 0.1–0.5% w/v for short-contact urogenital or wound-edge anesthesia in small-animal practice. The diluent is Sterile Water for Injection or 0.9% Sodium Chloride Injection that has been verified endotoxin-free; phosphate buffers are not used because divalent phosphate accelerates hydrolysis of the ester group. The solution is compounded in an ISO Class 5 laminar airflow hood according to USP <797> when prepared outside a GMP facility. The target pH is 3.5–4.5; at higher pH the unionized free base may precipitate as a haze, and at pH below 2.5 packaging leachables from low-density polyethylene containers increase. The compounded solution is filtered through a 0.22 µm polyvinylidene fluoride syringe filter into a sterile amber vial to reduce photolytic degradation. The prepared solution is assigned a beyond-use date of 24 h at room temperature or 7 days refrigerated under USP <797> risk-level guidance, unless stability data support longer storage. Particulate matter is inspected visually against USP <790>; subvisible counts above 10 particles/mL ≥ 10 µm require re-filtration. The terminal solution is not suitable for ophthalmic use because acidic pH damages corneal epithelium, and it is not injected intravenously. The product is a single-use veterinary dispensed preparation; repeated entry into a multi-dose vial is discouraged because contamination of the low-pH aqueous matrix may promote microbial growth in the absence of preservatives. Compatibility with plastic syringes is documented for 2 h contact time only; extended storage in polycarbonate syringes may reduce assay by 1–2% due to adsorption.